HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.
September 06, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Icecure Medical's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $3.
The reiteration of the 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Icecure Medical. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100